Frank Dolan

Diverse group of independent pharmacists shaking hands with Express Scripts representatives under a banner reading 'New Partnership Strategy' with a background of a vibrant community pharmacy.

Express Scripts Unveils Strategy Centered on Independent Pharmacies.

Frank Dolan May 27, 2024

An artistic representation of a handshake between two abstract figures representing Degron Therapeutics and Takeda over a background of molecular structures and chains symbolizing the development of molecule degraders for medical treatments.

Degron Therapeutics and Takeda Sign an Exclusive License and Partnership Deal to Create Molecule Degraders for Various Medical Conditions

Frank Dolan May 24, 2024

A futuristic laboratory scene illustrating a team of scientists analyzing data and celebrating the FDA approval for Phase III trial of LAE002 and LAE001 combination treatment for prostate cancer, with digital screens displaying molecular structures and trial protocol documents on the table.

FDA Greenlights Phase III Study Protocol for Combination of Laekna’s LAE002 and LAE001 in Treating Prostate Cancer.

Frank Dolan May 23, 2024

An illustrated conference scene visualizing the US Pharma and Biotech Summit 2024, featuring a diverse group of experts gathered around a large, futuristic, round table, with digital screens displaying innovative health policy strategies and election results in the background, set in a sleek, modern conference hall.

2024 US Pharmaceutical and Biotechnology Conference: Enhancing Health Policies Post-Election.

Frank Dolan May 22, 2024

A dynamic conference room scene with AI and biotech professionals gathered for the US Pharma and Biotech Summit 2024, featuring an interactive presentation on 'Artificial Intelligence and Machine Learning Through the Eyes of the FDA Part II' showcased on a large digital screen, with AI-driven robots and holographic medical innovations in the background.

2024 US Pharmaceutical and Biotechnology Conference: Exploring FDA Perspectives on Artificial Intelligence and Machine Learning Part II.

Frank Dolan May 21, 2024

Digital illustration of a bustling futuristic biotech summit, showcasing innovation in pharmaceuticals and biotechnology, with diverse scientists and entrepreneurs networking, surrounded by holographic displays of DNA structures, futuristic medical devices, and interactive virtual reality presentations on groundbreaking research, set in a sleek, modern conference center.

2024 US Pharmaceutical and Biotechnology Conference: An Overview of the Biotech Sector.

Frank Dolan May 17, 2024

2024 US Pharmaceutical and Biotechnology Conference: FDA Perspectives on Artificial Intelligence and Machine Learning.

Frank Dolan May 16, 2024

Novo Holdings Secures Majority Stake in Single Use Support to Broaden Life Science Instruments and Diagnostics Offerings

Frank Dolan May 15, 2024

A futuristic laboratory with scientists from AbbVie and Gilgamesh Pharmaceuticals collaborating around a holographic brain displaying advanced therapies for psychiatric disorders.

AbbVie and Gilgamesh Pharmaceuticals Reach Agreement to Collaborate on Developing Innovative Treatments for Mental Health Conditions.

Frank Dolan May 14, 2024

A futuristic conference room with marketing professionals gathered around a holographic display showcasing an innovative pharmaceutical campaign, integrating cutting-edge digital and traditional messaging strategies for 2024.

The Latest Communication Blend: An Overview of Pharmaceutical Marketing in 2024.

Frank Dolan May 13, 2024

A futuristic library with books and digital screens floating among researchers using advanced virtual reality equipment to study ancient texts.

Evading the Digital Era Impedes Research Progress.

Frank Dolan May 10, 2024

An artistic rendering of a futuristic laboratory where scientists from Flagship Pioneering and Metaphore Biotechnologies collaborate with Novo Nordisk to innovate cutting-edge obesity treatments, surrounded by advanced biotech equipment and digital health monitors displaying breakthrough data.

Flagship Pioneering and Metaphore Biotechnologies Enter Agreement with Novo Nordisk to Create Advanced Obesity Therapies

Frank Dolan May 9, 2024

A futuristic laboratory with scientists analyzing molecular structures and data on digital screens for LP-284 and RADR targeting NHL and other cancers.

Evaluating LP-284 alongside RADR in the Treatment of NHL and Various Specific Cancers.

Frank Dolan May 8, 2024

a futuristic laboratory with AstraZeneca and Cellectis logos, scientists collaborating on gene editing research

AstraZeneca Completes Equity Stake and Research Partnership with Cellectis.

Frank Dolan May 7, 2024

Illustration of a smiling doctor holding a bottle of Myhibbin oral suspension with organ transplant recipients in the background, showcasing a hopeful and positive atmosphere, with soft, soothing colors.

FDA Greenlights Azurity Pharmaceuticals’ Myhibbin in Liquid Form for Patients Receiving Organ Transplants

Frank Dolan May 6, 2024

An experienced executive presenting to a large audience in a futuristic conference room on advanced cell and gene therapy distribution strategies, with digital holograms of DNA strands and cell structures floating around them.

VP of Emerging Therapies at Cencora Talks About Distribution Strategies for Cell & Gene Therapies

Frank Dolan May 3, 2024

An artistic representation of diverse people coming together, hands joined in unity, with a backdrop of Walgreens and Boehringer Ingelheim logos, symbolizing their collaboration on enhancing clinical trial diversity.

Walgreens and Boehringer Ingelheim Collaborate to Improve Diversity in Clinical Trials.

Frank Dolan May 2, 2024

A futuristic, clean medical lab with scientists revealing the new high-concentration, citrate-free version of Cyltezo, Boehringer Ingelheim’s Humira biosimilar, shown with glowing vials, surrounded by holograms of chronic inflammatory diseases it treats.

FDA Grants Approval for Potent, Citrate-Free Cyltezo by Boehringer Ingelheim, a Biosimilar to Humira for Treating Chronic Inflammatory Conditions.

Frank Dolan May 1, 2024

FDA Clears Abbott’s Absorbable Stent System for Severe Ischemia in Lower Limb Arteries.

Frank Dolan April 30, 2024

Nurturing Innovation: A Biotech Executive’s Guide

Frank Dolan April 30, 2024

Stay up to date on the latest news

By pressing the Subscribe button, you confirm that you have read our Privacy Policy.

Iovance Biotherapeutics Stock Plummets 44%: What Investors Need to Know About 2025 Projections

Iovance Biotherapeutics Stock Plummets 44%: What Investors Need to Know About 2025 Projections

Insilico Medicine's Third Attempt at an IPO: Aiming Big in Hong Kong's Booming Biotech Market

Insilico Medicine’s Third Attempt at an IPO: Aiming Big in Hong Kong’s Booming Biotech Market

Biotech Sector Faces Major Workforce Cuts: Layoffs Surge as Firms Navigate Market Turbulence

Biotech Sector Faces Major Workforce Cuts: Layoffs Surge as Firms Navigate Market Turbulence

Email Us

info at arsenal-advisors.com

Headquarters

Cambridge, MA USA